 Home > Active Ingredient News > Immunology News > Front Cell Dev Biol: HSA_CIRC_0000652 aggravates the inflammatory response in ankylosing spondylitis by activating macrophages and enhancing OX40/OX40L interaction

Front Cell Dev Biol: HSA_CIRC_0000652 aggravates the inflammatory response in ankylosing spondylitis by activating macrophages and enhancing OX40/OX40L interaction

 Last Update: 2022-01-22
 Source: Internet
 Author: User

Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

High Purity 99% BPN14770 Zatolmilast 1606974-33-7 In Stock Fast Ship to USA

CAS No.: 1606974-33-7

Pharm Grade

$1-1.1/UNIT FOB

High quality Thymosin α1 Pure CAS 62304-98-7 Thymosin Alpha 1 Thymalfasin

CAS No.: 62304-98-7

Pharmacy Grade

$12-15/UNIT FOB

Top quantity Imiquimod CAS NO 99011-02-6 White crystalline powder 99% API

CAS No.: 99011-02-6

Pharmacy Grade

$1800-1850/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.